FAFoat Sh. Akhmetzyanov

Foat Sh. Akhmetzyanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Foat Sh. Akhmetzyanov has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preliminary results of neoadjuvant chemotherapy in resectable gastric cancer

    by F.SH. Akhmetzyanov, N.V. Fedotova, V.I. Egorov

    Neoadjuvant chemotherapy (NAC) for resectable gastric cancer (GC) has demonstrated benefits in survival rates in key studies. The safety and risks of neoadjuvant chemotherapy (NAC) remain a matter of debate. Objective. Evaluate the immediate results of chemotherapy in resectable gastric cancer. Material and methods. The retrospective analysis included 247 patients who underwent combined treatment for resectable GC. 149 patients went to the NAC group, 98 patients to the adjuvant chemotherapy (AC) group. Complications were assessed using the Clavien-Dindo intraoperative risk scale, the degree of pathomorphological response was assessed using the Mandart scale, and adherence to AC was determined. Results. Complications of NAC were reported in 36 (24.2%) patients, and no cases of severe toxicity or mortality were detected. A pronounced pathomorphological effect (TRG 1—2) was detected in 37 (25.0%) patients. Clinically significant postoperative complications (Clavien-Dindo>II) were reported in 9.4% in the NAC group and in 15.3% in the AC group. Pathomorphological stage I was registered in 30.9% of the NAC group compared with 5.1% in the AC group (p<0.001). Conclusion. Conducting NACT in gastric cancer demonstrates an acceptable toxicity profile and provides a pronounced pathomorphological effect without increasing surgical risks.

  • Open Access

    Risk factors and clinical significance of diabetes mellitus developed after pancreaticoduodenectomy for pancreatic cancer

    by V. I. Egorov, A. G. Kotelnikov, Yu. I. Patyutko, F. Sh. Akhmetzyanov, A. N. Polyakov, N. E. Kudashkin, В. И. Егоров, А. Г. Котельников, Ю. И. Патютко, Ф. Ш. Ахметзянов, et al.

    BACKGROUND: Diabetes mellitus (DM) is a clinically significant long-term complication of pancreatoduodenectomy (PD); however, its incidence, risk factors for its development, and its impact on oncological outcomes remain insufficiently studied. AIM: To evaluate risk factors for diabetes mellitus in patients undergoing pancreatoduodenectomy and to determine its clinical significance. MATERIALS AND METHODS: A two-center retrospective cohort study was conducted, including 544 patients who underwent PD between 2011 and 2024. Clinical, demographic, intraoperative, and morphological parameters were analyzed. Univariate and multivariate regression analyses were used to identify predictors of DM and to assess survival. The predictive performance of the model was evaluated using ROC analysis. RESULTS: The overall incidence of DM among patients without pre-existing diabetes mellitus was 15.3% (83/544). Independent predictors for the development of DM were: age 67 years and older (OR 1.069; 95% CI: 1.029–1.110; p=0.001), stable angina pectoris (OR 2.554; 95% CI: 1.172–5.562; p=0.018), diameter of the Wirsung duct (≥0.5 cm) (OR 5.84; 95% CI: 1.399–24.45; p=0.016), complications of Clavien–Dindo grade ≥ IIIA (OR 8.9; 95% CI: 3.9–20.3; pCONCLUSION: Diabetes mellitus following pancreatoduodenectomy for pancreatic head and periampullary cancers is a relatively uncommon (15.3%) but clinically significant complication. Preoperative assessment of the risk for this complication and careful postoperative metabolic monitoring are necessary.

  • Frailty assessment scales for perioperative prognosis in pancreaticoduodenectomy

    by V. I. Egorov, A. G. Kotelnikov, B. F. Rakhmatullin, F. Sh. Akhmetzyanov, A. V. Pasheev, A. N. Polyakov, A. K. Saetgarayev

    Pancreaticoduodenectomy (PD) is associated with high rates of postoperative complications (30–50%) and mortality (2–5%), while traditional risk factors do not adequately reflect a patient’s functional reserve. Frailty assessment is considered a promising approach for perioperative prediction. This review analyzes 35 publications (2014–2025) on frailty scales in patients undergoing PD. The most studied tools were the modified frailty index (mFI-11 and mFI-5), Clinical Frailty Scale (CFS), Edmonton Frail Scale (EFS), Comprehensive Geriatric Assessment (CGA), Risk Analysis Index (RAI), and Fried frailty phenotype. CFS showed the strongest association with mortality (OR 4.89; 95% CI 1.83–13.05), EFS with postoperative complications (OR 2.93; 95% CI 1.52–5.65), and the Fried phenotype with postoperative delirium (OR 3.79). mFI-5 > 2 was associated with increased mortality (OR 2.08) and reduced median overall survival (21.3 vs 42.1 months). mFI-11 > 0.27 was an independent predictor of complications (OR 1.544) and 30-day mortality (OR 1.536). However, the key finding is low sensitivity of all scales: in a comparative study of seven instruments, sensitivity ranged from 21.5% to 38.5% with specificity of 76.7–92.4%. In the largest PD cohort (n = 9986), frailty by mFI ≥0.27 was detected in only 6.4% of patients – 4–6 times lower than the expected prevalence. RAI-C at threshold ≥21 had sensitivity 0.50, RAI-A – 0.25. Thus, existing scales miss 60–80% of frail patients (especially those with prefrailty), raising doubts about their clinical utility as standalone screening tools. The strongest association with mortality was achieved for CFS, with complications – for EFS, with survival – for mFI-5. Given the low sensitivity, the most reasonable strategy is to perform extended geriatric assessment in all patients aged 65–70 years or older without prior screening, who will undergo PD.

  • Open Access

    Outcomes of anterior and intersphincteric resection for rectal cancer: focus on the issue of permanent stoma

    by Vasiliy I. Egorov, Foat Sh. Akhmetzyanov, David M. Ruvinsky, Alina I. Gilyazova, Darya V. Dimitrieva, Vitaliy V. Strunkin

    AIM: to assess early and long-term outcomes of interspincteric (ISR) and ultralow anterior resection (ULAR) for low rectal cancer, with a special focus on risk factors for a permanent stoma. PATIENTS AND METHODS: seventy patients who underwent ISR/ULAR for rectal cancer from January 2019 to December 2023 were included in retrospective study. Patients who underwent ULAR during the same time period was selected after matching by the following parameters: gender, age, body mass index, comorbidities, type of surgical approach, pTNM, tumor stage, degree of differentiation, distance of the tumor from the anus, type of neoadjuvant radiation therapy (n = 58). The overall median follow-up of patients in both groups was 38 (95% CI: 31–41) months. Surgical complications, stoma formation rate, three-year overall (OS) and three-year recurrence-free survival (RFS) were assessed. Multivariate logistic regression analysis was used to identify predictors of permanent stoma. RESULTS: anastomotic leakage was higher after ULAR: 17/58 (29.3%) vs. 10/70 (14.3%) (p = 0.038). Late complications, predominantly functional disorders, occurred more often after AAR: 35/67 (52.2%) vs. 14/55 (25.5%) (p = 0.003). Despite higher odds of stoma reversal after ULAR (odds ratio (OR) 6.5; 95% confidence interval (CI) 1.7–23.9), by the end of follow-up, a greater proportion of patients in this group were living with a permanent stoma: 27/56 (48.2%) vs. 15/67 (22.4%) (p = 0.003). Independent predictors of a permanent stoma were the performance of ULAR (adjusted odds ratio (AOR) 3.54; 95 CI: 1.373–9.13), anastomotic leakage (AOR 11.76; 95 CI: 3.46–40), pN + stage (AOR 1.73; 95 CI: 1.06–2.82) and radiotherapy (AOR 3.92; 95 CI: 1.17–13.09). The prognostic model showed high discriminative ability (Area Under the Curve (AUC) = 0.851; 95% CI: 0.772–0.929). Three-year OS (63.9% (95% CI: 49.9–74.9) vs. 75.0%, (95% CI: 59.7–85.2), p = 0.503) and RFS (48.2% (95% CI: 33.9–61.2) vs. 50.3% (95% CI: 31.2–66.7), p = 0.646) after AAR and ULAR, respectively, were statistically comparable. CONCLUSION : despite comparable oncological efficacy, ULAR is associated with a higher risk of anastomotic leakage, which is a key factor leading to a permanent stoma. AAR is associated with a higher rate of functional disorders. The choice of surgical technique should be based on an individual assessment of the risk of anastomotic leakage.

  • Assessment of the prognostic significance of positron emission tomography combined with computed tomography at different stages of treatment in patients with non-Hodgkin lymphomas: a cohort study

    by Foat Sh. Akhmetzyanov, Sergey V. Boichuk, Angelina V. Karamanian, Ахметзянов Фоат Шайхутдинович, Бойчук Сергей Васильевич

    Background: The Russian Federation is experiencing an increase in the incidence of tumors of lymphoid and hematopoietic tissues; however, no unified diagnostic or treatment algorithm has been developed for these conditions. Aim: To determine effective diagnostic and therapeutic approaches, as well as criteria for early treatment adaptation, in patients with nonHodgkin lymphomas. Methods: The medical records of 439 patients with two histological types of nonHodgkin lymphomas who received inpatient treatment and followup at the Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan over a 10year period were retrospectively reviewed: 386 patients with aggressive lymphoma (diffuse large Bcell lymphoma) and 53 patients with indolent lymphoma (follicular lymphoma). There were 237 patients (54.0%) aged over 60 years and 89 (20.2%) aged over 70 years. A total of 259 patients underwent three positron emission tomography combined with computed tomography (PET/CT) scans (primary, interim, and final). Inclusion criteria were: age ≥18 years; no prior treatment for nonHodgkin lymphoma; and a histologically and immunohistochemically confirmed diagnosis. Exclusion criteria were: acute somatic or infectious diseases (including HIV infection) ; severe cognitive impairment; refusal to participate in the study; and residence outside the region. Statistical analysis was performed using IBM SPSS Statistics and Statistica 10 software. Normality of distribution was tested using the Kolmogorov–Smirnov test. Survival was assessed using the Kaplan–Meier method. Differences were considered statistically significant at р 0.05. Results: Changes in the maximum standardized uptake value (SUVmax) on interim PET/CT were shown to be associated with the risk of progression and with overall survival rates, which decreased significantly with increasing disease stage. Assessment of the metabolic response at the interim stage using the Deauville scale demonstrated high prognostic significance: scores of 1–3 identified a group of patients with complete metabolic remission. However, even when a pronounced tumor response was achieved, some patients developed severe cumulative toxicity. Specifically, in a group of 120 patients who continued treatment after the fourth cycle, highgrade febrile neutropenia was recorded in 11 patients (9.2%), and in 10 of these cases (8.3%) it was accompanied by fatal complications due to multiple organ failure. Conclusion: These findings underscore that in patients who achieve a complete metabolic response but have signs of severe cumulative toxicity, reducing the planned volume of chemotherapy should be considered to improve treatment safety.

  • Open Access

    Strategies for infusion therapy in pancreaticoduodenectomy (literature review)

    by B. F. Rakhmatullin, V. I. Egorov, F. Sh. Akhmetzyanov, A. V. Pasheev

    Introduction . Fluid therapy is an integral component of anesthetic and resuscitation management in the early perioperative period following abdominal oncological surgery. Optimizing fluid therapy remains particularly challenging in hepatopancreatobiliary surgery, particularly during pancreaticoduodenectomy (PD). Currently, there is no consensus in the scientific community regarding the optimal regimen and strategy for fluid therapy during PD. The objective was to analyze the clinical efficacy of different infusion therapy strategies in PD. Materials and methods. A review of studies, systematic reviews, meta-analyses, and clinical guidelines on fluid therapy during pancreaticoduodenectomy was conducted. The search was conducted using PubMed, the Cochrane Controlled Clinical Trials Register, Google Scholar, and e-Library (for Russian authors). Studies from the past ten years were primarily reviewed. Inclusion criteria for the review were text publications comparing restrictive, targeted, and liberal perioperative fluid therapy in patients undergoing PD. Exclusion criteria were duplicates, abstracts, abstracts without a full-text version, and publications not related to the study objective. Results . Perioperative fluid therapy is a critical factor significantly affecting PD outcomes. Both excessive (liberal) and overly restrictive fluid regimens are associated with an increased risk of postoperative complications, including those specific to PD. An optimal fluid therapy strategy for PD should be balanced, avoiding both hyperand hypovolemia, and take into account individual patient risk factors (pancreatic duct diameter, pancreatic consistency, albumin level). Conclusion . A modern approach to the strategy of infusion therapy in PD should be personalized, physiologically justified and dynamically controlled and based on a constant assessment of the balance between ensuring adequate organ perfusion and preventing iatrogenic hyperhydration.

  • Open Access

    Tumor location and histogenesis as risk factors for early complications and mortality following multivisceral surgical procedures with pancreatoduodenectomy

    by V. I. Egorov, А. Г. Котельников, Yu. I. Patyutko, F. Sh. Akhmetzyanov, N. E. Kudashkin, A. N. Polyakov, D. M. Ruvinskiy, D. V. Podluzhny, Ю. И. Патютко

    Aim. To investigate the role of tumor localization and histogenesis as risk factors for postoperative complications and mortality following multivisceral surgical procedures involving pancreaticoduodenectomy.Materials and Methods. This study included all patients (n = 251) who underwent multivisceral surgery with pancreaticoduodenectomy for tumors of various localizations at two medical institutions.Results. Comparative analysis of pancreatic parenchymal density revealed statistically significant differences between pancreatic cancer and cancer of the major duodenal papilla (p = 0.012), distal common bile duct cancer (p = 0.040), duodenal tumors (p < 0.001), secondary pancreatic tumors (p < 0.001), colorectal cancer (p < 0.001), renal cancer (p = 0.027), and gastric cancer (p < 0.001). Statistically significant differences were also observed in the following pairwise comparisons: major duodenal papilla cancer vs. colorectal cancer (p = 0.010); neuroendocrine tumor of the pancreatic head vs. colorectal cancer (p < 0.001); pancreatic neuroendocrine tumor vs. gastric cancer (p = 0.006). For pancreatic duct diameter, significant differences were found between duodenal tumors and pancreatic cancer (p = 0.016), colorectal cancer and pancreatic cancer (p < 0.001), gastric cancer and pancreatic cancer (p = 0.016). The overall rate of postoperative complications in the study group was 65.7% (n = 165), with a mortality rate of 7.2% (n = 18). The likelihood of developing a postoperative pancreatic fistula was significantly higher in patients with distal common bile duct cancer (AOR 5.9; 95% CI: 1.4–24.6, p = 0.015), secondary malignancies of the pancreatic head (AOR 4.7; 95% CI: 1.06–21.0, p = 0.041), and gastric cancer (AOR 2.8; 95% CI: 1.048–7.691, p = 0.040). The risk of dehiscence of pancreatic-digestive anastomosis significantly increased in patients with distal common bile duct cancer (AOR 7.8; 95% CI: 1.7–35.05, p = 0.007). In patients with secondary malignancies of the pancreatic head, postoperative mortality was significantly higher (AOR 9.7; 95% CI: 1.79–52.8, p = 0.008).Conclusion. Tumor localization and histogenesis may serve as independent predictors of early outcomes following multivisceral surgery with pancreatoduodenectomy. Cancer of the pancreatic head generally has the most favorable prognosis among pancreatic tumors, and its location is associated with a lower risk of postoperative complications. In contrast, surgeries for distal common bile duct cancer, metastatic lesions of the pancreatic head, and gastric cancer are associated with significantly worse short-term outcomes.

  • Multivisceral surgeries with pancreatoduodenectomy for gastric cancer: immediate and long-term results

    by V.I. Egorov, A.G. Kotelnikov, Yu.I. Patyutko, F.SH. Akhmetzyanov, D.V. Podluzhny, A.N. Polyakov, N.E. Kudashkin, N.T. Shaikhutdinov

    Objective. To study the immediate and long-term results of multivisceral surgeries with pancreaticoduodenectomy for gastric cancer. Material and methods. The 1st group included 24 patients who underwent multivisceral surgeries with pancreaticoduodenectomy for gastric cancer with pancreatic head and/or duodenum invasion. The 2nd group included 60 patients with gastric cancer who underwent partial resection of the pancreatic head and/or duodenum rather pancreaticoduodenectomy. Results. ASA class III was observed in 10 (41.7%) out of 24 patients in the 1st group and in 12 (20.0%) out of 60 patients in the 2nd group (p=0.041). In group 2, there were no cases of vein invasion (0 versus 12.5%; p=0.021). In group 1, Clavien-Dindo grade ≥3 complications were more common (10 (41.7%) vs. 14 (23.3%) cases, p=0.005). Moreover, pancreatic fistulas of all classes were more common (9 (37.5%) vs. 9 (15.0%) cases, p=0.023). Median overall survival was 15 and 14 months, respectively. Overall five-year survival was 24.1% (95% CI 7.8—45.2) and 8.2% (95% CI 2.3—18.9%), respectively (p=0.483). Locoregional recurrence was more common in the 2nd group (23 (41.8%) out of 55 vs. 3 (13.6%) out of 23 patients, p=0.018). In the 1st group, median overall survival without adjuvant chemotherapy was 13 months (95% CI 5—17), in the group with adjuvant chemotherapy — 37 months (95% CI 14—64). Overall five-year survival was 7.7% (95% CI 5—29.2) and 50.0% (95% CI 13.7—78.5), respectively (p=0.003). Median overall survival in the 2nd group without adjuvant chemotherapy was 13 months (95% CI 5—17), in the 2nd group with chemotherapy — 17 months (95% CI 12—29; p=0.016). The risk of death in the 2nd group with chemotherapy was lower than in the 1st group without chemotherapy (OR 0.385; 95% CI 0.183—0.809; p=0.012). Multivariate analysis in the 1st group revealed that ASA class 3 negatively affected overall survival (OR 3.04; 95% CI 1.04—8.81; p=0.040). Multivariate analysis after combining both groups established that negative factors of long-term prognosis were female gender (OR 2.47; 95% CI 1.25—4.87; p=0.009), coronary artery disease (OR 3.44; 95% CI 1.16—10.17; p=0.025), locoregional recurrence (OR 2.49; 95% CI 1.13—5.50; p=0.024) and type B pancreatic fistula (OR 2.68; 95% CI 1.070—6.731; p=0.035). Positive factors were multivisceral surgeries with pancreaticoduodenectomy (OR 0.36; 95% CI 0.14—0.86; p=0.023) and adjuvant chemotherapy (OR 0.27; 95% CI 0.13—0.57; p<0.001). Conclusion. Multivisceral surgeries with pancreaticoduodenectomy for gastric cancer with pancreatic and/or duodenal invasion is justified in patients with ASA class 1—2 due to higher probability of adjuvant chemotherapy and better survival.


  • Open Access

    Multivisceral surgery for ductal adenocarcinoma of the pancreatic head: early and long-term outcomes

    by V. I. Egorov, А. Г. Котельников, Yu. I. Patyutko, F. Sh. Akhmetzyanov, D. V. Podluzhny, N. E. Kudashkin, A. N. Polyakov, D. M. Ruvinskiy, Ю. И. Патютко

    Aim. To evaluate the early and long-term outcomes of multivisceral surgery for ductal adenocarcinoma of the pancreatic head.Materials and methods. Group 1 (main group) included 63 patients who underwent multivisceral surgery for ductal adenocarcinoma of the pancreatic head. Group 2 (control group) consisted of 442 patients with ductal adenocarcinoma of the pancreatic head who underwent standard pancreatoduodenectomy. Patients with stage IV tumors were excluded.Results. Immediate outcomes were comparable between the groups, except for a higher incidence of intra-abdominal abscesses in Group 1 (12.7% vs. 2.1%; p < 0.001). Postoperative mortality differed insignificantly (6.3% vs. 4.3%; p = 0.465). The median overall survival in Group 1 was 22 months compared to 33 months in Group 2, and the 5-year overall survival rates were 9.1% and 20.4%, respectively (p = 0.001). The frequency of adjuvant chemotherapy administration (p = 0.285) and the median number of chemotherapy cycles (p = 0.446) differed insignificantly between the groups. The 5-year overall survival among patients who received adjuvant chemotherapy was 13.3% in Group 1 and 19.4% in Group 2. The median overall survival in these groups was 30 and 35 months, respectively (p = 0.108). In Group 2, the median overall survival without neoadjuvant chemotherapy was 35 months, compared to 31 months with neoadjuvant chemotherapy (p = 0.411).Conclusion. Multivisceral resections involving pancreatoduodenectomy for ductal adenocarcinoma of the pancreatic head are associated with comparable immediate outcomes to standard pancreatoduodenectomy without adjacent organ resection. These outcomes are comparable only when the procedures are performed in specialized centers and when adequate adjuvant chemotherapy is administered; without it, survival rates following multivisceral surgery were significantly lower. Indications for multivisceral procedures require a personalized approach that takes into account all prognostic factors.

  • Open Access

    Immediate outcomes of pancreatoduodenalectomy in multivisceral surgery with vascular resection

    by V. I. Egorov, А. Г. Котельников, Yu. I. Patyutko, F. Sh. Akhmetzyanov, A. N. Polyakov, N. E. Kudashkin, D. V. Podluzhny, Ю. И. Патютко

    Purpose: to study the immediate outcomes of pancreaticoduodenalectomy (PD) in multivisceral surgeries (MVS) with vascular resections. Material and Methods. The study included 145 patients who underwent pancreaticoduodenalectomy with resection of the major vessels, including the superior mesenteric vein, the portal vein, and the inferior vena cava. These patients were divided into two groups. The main group included 32 patients who underwent MVS with PD, and the control group consisted of 113 patients who underwent PD. Results. There were no statistically significant differences in the immediate outcomes between two groups. Pancreatic fistula developed more often in the MVS with PD group than in the PD group (25 vs 11.5 %, p=0.055). The incidence of resected vein thrombosis in the main group was 9.4 %, in the control group was 1.8 % (p=0.07). Postoperative intra-abdominal bleeding was 6.2 % vs 8 % (p=1.0). Postoperative mortality was 6.2 % in the MVS with PD group and 8.8 % in the PD group (p=1.0). True vascular invasion was confirmed by pathomorphological examination in 20 (64.5 %) cases in the MVS with PD group and in 81 (71.7 %) cases in the PD group (p=0.44). Conclusion. Although no statistically significant differences were observed between the two groups, venous resections in multivisceral surgeries involving pancreaticoduodenalectomy demonstrated a higher incidence of pancreatodigestive anastomosis complications and a higher frequency of venous thrombosis compared to pancreaticoduodenalectomy without resection of adjacent organs, which must be taken into account when planning surgery and managing the postoperative period of this category of patients.